Psyence doses first patient in Phase 2b psilocybin trial for cancer-related adjustment disorder

Psyence Biomedical Ltd. (PBM) — Psyence Biomedical said the first patient was dosed in its Phase 2b trial evaluating NPX-5, a 25 mg nature-derived psilocybin product, for adjustment disorder in cancer patients in palliative care.

The milestone follows the company's recent expansion of its Australian site network. The dosing marks tangible clinical progress for one of the smaller Nasdaq-listed psychedelic developers amid heightened sector attention.

Source: sec.gov

For the rest of that week's sector news, read our week in review.